NASDAQ · LNSRHealthcareSurgical Instruments

LENSAR financials

$6.90+0.29%
Close Sep 29, 2026 · split-adjusted

Revenue

Net income

Income statement & cash flow

Fiscal yearFY25
Dec 31
FY24
Dec 31
FY23
Dec 31
FY22
Dec 31
FY21
Dec 31
FY20
Dec 31
Revenue$58.4M$53.5M$42.2M$35.4M$34.5M$26.4M
Gross profit$27.1M$25.9M$21.1M$20.0M$17.8M$14.1M
Gross margin46.4%48.3%50.1%56.4%51.8%53.4%
Operating income-$24.6M-$10.7M-$12.2M-$20.2M-$19.7M-$18.5M
Net income-$34.3M-$31.4M-$14.4M-$19.9M-$19.6M-$19.8M
Net margin−58.7%−58.7%−34.1%−56.3%−56.9%−75.0%
Diluted EPS$-2.87$-2.73$-1.31$-1.96$-2.09$-4.28
EBITDA-$20.1M-$3.0M-$8.7M-$16.3M-$16.4M-$15.4M
Operating cash flow-$14.8M-$2.3M-$9.7M-$14.9M-$9.0M-$13.8M
Free cash flow-$14.9M-$2.4M-$9.9M-$15.0M-$9.3M-$14.2M
Diluted shares12.0M11.5M11.0M10.2M9.4M4.6M

Balance sheet

Period endDec 31Dec 31Dec 31Dec 31Dec 31Dec 31
Cash & equivalents$13.0M$16.3M$20.6M$14.7M$31.6M$40.6M
Short-term investments$5.0M$6.2M$3.4M$0.00—$0.00
Total debt$0.00$0.00$0.00$0.00$0.00$0.00
Total assets$71.4M$66.3M$69.6M$55.8M$66.5M$79.1M
Total liabilities$83.7M$47.7M$22.4M$13.9M$11.6M$11.9M
Shareholders' equity-$26.0M$4.9M$33.4M$42.0M$54.9M$67.2M

From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology